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Many a clinical intervention thrives on placebos.  Lack of consensus — both definitional and 
methodological — however, contributes to general confusion and specious conclusions regarding 
the legitimacy and relevance of placebos in modern medicine. The apparent divergence between 
objective and subjective treatment outcomes, moreover, renders placebos clinically meaningless. 
Asthma provides a clinical model for studying placebos because it highlights how psychology 
works in concert with pharmacology. Here we examine placebos as valuable adjuncts to, rather 
than replacements for, pharmacological treatments.
Introduction
Wechsler et al. (2011) distinguish objective from 
subjective measures of lung function; their find-
ings, however, fuel confusion about placebos, es-
pecially in the context of asthma (Gorski, 2011). 
The present piece highlights the role of placebos 
in asthma.  Specifically, we argue for the value of 
subjective factors as well as the presence of objec-
tive placebo effects and responses in medicine.
Misnomers and Placebos 
Discrepancies on what constitutes a “placebo” un-
derlie much of the controversy surrounding the 
relevance of placebo effects to modern medicine. 
The word “placebo” surfaced in the early 1800’s as 
a medical term denoting treatment for ailments 
that doctors considered to be “all in the head” and 
were otherwise powerless to treat (Harrington, 
2008).  This definition instilled the widespread 
belief that placebos were mere “nothings” — tools 
to pacify the difficult and deluded.
Though this impression remains pervasive, 
what constitutes a “placebo” extends well beyond 
inert pills or injections.  In fact, one may de-
fine placebo more broadly as that which confers 
a benefit explained by neither disease-specific 
pharmacologic activity nor natural phenomena 
such as spontaneous remission.  Construed in 
this fashion, placebo could arguably represent 
the whole history of medicine prior to its shift to 
evidence-based intervention (Shapiro & Shapiro, 
1997).  Even contextual features of modern medi-
cal treatments contribute to healing.  Seemingly 
simple cues such as pill-colour can mediate the 
patient response — blue placebo pills can act like 
depressants, reducing heart rate amongst unsus-
pecting medical students (Blackwell, Bloomfield, 
& Buncher, 1972).  Brand-name pills act more effec-
tively than their no-name equivalent (Branthwaite 
& Cooper, 1981).  Discounted prices can diminish 
the effectiveness of energy drinks (Shiv, Carmon, 
& Ariely, 2005) and a more expensive painkiller 
exerts greater analgesic power, increasing shock 
tolerance thresholds in healthy subjects (Waber, 
Shiv, Carmon, & Ariely, 2008).  Dose perception 
also contributes to healing; patients who ingested 
four placebos a day showed a marked improve-
ment over those who took two (De Craen et al., 
1999).  Such findings suggest that placebos are al-
ready active in current therapeutic interventions.
Evidently, placebos are not “nothings”, nor 
must one administer an actual inert substance 
to achieve a “placebo effect” (Miller & Kaptchuk, 
2008).  Dr. Gorski — a surgical oncologist, and 
panel-member at TAM — was thus correct in as-
serting “the term ‘placebo effect’ is a misnomer”, 
but not for the reasons he cites: 
[The term “placebo effect”] implies that 
there is a true physiologic effect caused by 
an inert intervention.  “Placebo response” 
or “placebo responses” seemed to us a 
better term because what we are observ-
ing with a placebo is in reality a patient’s 
subjective response to thinking that he is 
having something active done.  In general, 
we do not see placebo responses [improv-
ing] objective outcomes; i.e., prolonged 
survival in cancer.
To begin with, the term “placebo effect” 
should not be singular.  The diverse set of changes 
that accompany each individual treatment and 
The Journal of
TAM 
The Amazing Meeting — an 
international conference on 
critical thinking dedicated 
to subjecting scientific 
advances to rigorous scru-
tiny. At TAM 2011 in Las 
Vegas, skeptics convened 
to discuss the merits and, 
moreso, the limitations of 
placebo. A summary of the 
discussion can be found at 
http://www.sciencebased-
medicine.org/index.php/
spin-city-placebos-and-
asthma/. 
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disease escape the reaches of one explicable and 
reproducible “placebo effect” (Wampold, Minami, 
Tierney, Baskin, & Bhati, 2005).  Certain diseases 
are more amenable to the effects of expectation 
and suggestion than others.  For example, the pla-
cebo group comprises almost 100% of the drug 
effect in the antidepressant treatment for mild-
to-moderate depression (Fournier et al., 2010; 
Khan, Leventhal, Khan, & Brown, 2002; Kirsch et 
al., 2008; Rief et al., 2009) but represents close to 
none of the improvement elicited by treating strep 
throat with penicillin (e.g. Zwart et al., 2000). 
Perceiving placebo effects as a unitary phenom-
enon spurs many individuals to misconstrue all 
placebo effects as illusory and merely subjective 
(Harrington, 2006).  Acknowledging that the 
term “placebo effect” encompasses a multiplicity 
of manifestations according to disease and indi-
vidual warrants a more nuanced analysis.
With his account, Dr. Gorski dismisses the 
term placebo “effect” in favour of “response” when 
in fact the correct distinction between effect and 
response is of an entirely different ilk.  In the con-
text of a randomized controlled trial (RCT), “pla-
cebo response” encompasses the full change in 
the group receiving the inert pill.  “Placebo effect” 
refers to the difference between the placebo re-
sponse and the no-treatment group (Kirsch, 1997; 
Kirsch & Sapirstein, 1998; Raz, 2007).  Without 
comparing the placebo group to a no-treatment 
group, factors such as natural disease progression 
and regression to the mean confound the placebo 
effect.  Achieving definitional consensus is key to 
a coherent interpretation of past and future pla-
cebo research.
Objective Measures of  
Placebo Effects
The recent study by Wechsler et al. demonstrates 
that self-reporting does not align with objective 
measures of lung function (FEV1) in mild asthma. 
Sham bronchodilator and acupuncture conferred 
no measurable benefit over no-treatment, but 
were indistinguishable from active bronchodila-
tor according to subjective reports.  These seem-
ingly clear observations may prompt the spurious 
conclusion that all placebo effects are purely “sub-
jective”, with objective measures failing to cor-
roborate self-reported change.  As per Dr. Gorski: 
Real medicine produces real, objectively 
measurable changes in physiology to-
wards a more normally functioning state.  
Placebo medicine does not.  In any ratio-
nal, science-based discussion, this would 
be the end of the story.
 The existing literature provides only tenu-
ous support for this premature conclusion, par-
ticularly in light of budding research investigat-
ing the biological ramifications of the interaction 
between the nervous and immune systems — the 
“mind–body connection” (Sternberg 1997). 
Identifying how psychological processes such as 
stress, emotions and expectations may influence 
other bodily processes is central to establishing 
placebo effects as scientific phenomena beyond 
“magical thinking”.  Extensive anatomical con-
nections between nervous and immune systems 
(Goetzl, Chernov et al. 1985; Payan and Goetzl 
1987; Felten and Felten 1991) motivated animal 
studies on the nature of their relationship.  These 
efforts revealed endogenous chemicals such as 
certain proteins, hormones and neurotransmit-
ters as mediators of this interaction (MacPhee, 
Antoni et al. 1989; Sternberg, Hill et al. 1989; 
Sternberg, Young et al. 1989; Edwards, Yunger et 
al. 1991; Misiewicz, Poltorak et al. 1997).  Although 
these studies focused on animals, they relate to 
placebo effects in humans by demonstrating that 
the mammalian nervous system possesses the 
anatomical and functional connections necessary 
to exert profound effects on the rest of the body.  
In human subjects, placebo scientists often 
distinguish between placebo effects resulting 
from expectation and those arising from condi-
tioning.  With classical conditioning, pairing con-
textual cues with drug administration can later 
permit these cues to elicit a response mimicking 
drug action; a process evident in both conscious 
afflictions such as pain and motor impairment, 
and unconscious processes such as hormone se-
cretion (Ader and Cohen 1985; Benedetti, Pollo et 
al. 2003).  In one particular immunology study, 
after pairing an intravenous immunosuppres-
sant (US) with anise-flavored syrup (CS), leuko-
cyte counts in 80% of multiple sclerosis patients 
dropped significantly in response to the admin-
istration of the CS alone (Giang, Goodman et al. 
1996).  Additional studies confirmed that inert 
substances enable robust and objective immuno-
suppression and immunostimulation via behav-
ioral conditioning mechanisms (Pacheco-Lupez, 
Engler et al. 2006). 
Beyond conditioned reactions, suggestion 
and expectation also exert physiological thera-
peutic effects.  For instance, in patients with 
Parkinson’s disease, the expectation that an in-
jection would ameliorate motor function objec-
tively triggered increased dopamine levels in the 
brain (de la Fuente-Fernandez, Ruth et al. 2001). 
Preliminary studies show that verbal sugges-
tion can also modulate processes such as blood 
pressure and gastric function (Meissner, 2011). 
Placebo Effect 
The difference between 
changes in the placebo and 
no-treatment groups. 
Placebo Response 
The change measured in 
the placebo group.
FEV1 
Forced Expiratory Volume 
in 1 second — a measure of 
lung function based on the 
amount of forced air exhaled 
over a one-second period.
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Clearly, psychological processes such as expecta-
tion impact physiology over and above subjective 
experience, and yet Dr. Gorski asserts: 
This issue of placebo responses being ob-
served only in subjective patient-report-
ed clinical outcomes (pain, anxiety, and 
the like) and not in objectively measured 
outcomes is an important one . . . as Mark 
Crislip so humorously pointed out, the 
placebo response is the beer goggles of 
medicine.
In reality, even the clinical manifestation of 
pain — as the ultimate subjective measure — has 
a physiological basis.  Surreptitious inhibition of 
endogenous opioids, the body’s internal brand of 
morphine, leads to blockade of pain-relieving pla-
cebo effects (Amanzio & Benedetti, 1999; Levine, 
Gordon, & Fields, 1978).  PET and functional 
magnetic resonance imaging (fMRI) studies cor-
roborate these findings (Zubieta & Stohler 2009). 
Strikingly, naloxone, the opioid antagonist agent 
in these studies, also blocked a common second-
ary effect of these neurotransmitters: respiratory 
depression (Benedetti, Amanzio et al. 1999).  The 
placebo-induced modulation by endogenous opi-
oids on the respiratory system strengthens the 
notion that the brain instigates direct and objec-
tively measurable effects on the rest of the body, 
and contradicting Dr. Gorski’s assertion that 
“Placebos don’t work in asthma.”
In fact, the underlying physiology of asthma 
provides the biological model for mind–body ef-
fects.  Immune and inflammatory pathways are 
major contributors to airway function in asthma, 
and are highly susceptible to conditioning and 
other psychological processes.  Specifically, stress 
is a key component and mediator of the immune 
system (Chen & Miller, 2007).  Studies of inflam-
matory diseases such as rheumatoid arthritis re-
veal that stress can, depending on duration and 
intensity, both enhance and depress immune 
function (Potter & Zautra, 1997; Straub, Dhabhar 
et al. 2005).  More particular to asthma, research 
indicates that stress amplifies immune response 
(Chen & Miller, 2007; Liu et al., 2002).  A study 
of asthmatic college students showed that stress 
during an exam period led to greater eosinophil 
counts in the blood and sputum of the students 
(Liu, et al., 2002).  There are several possible 
pathways that mediate this interaction (Chen & 
Miller, 2007; Miller & Wood, 2003).  Some posit 
that irregular HPA-axis activity responsible for 
the low, flat cortisol response to stress in asth-
matic patients could underlie the symptoms trig-
gered by intense emotions (Buske-Kirschbaum, 
von Auer et al. 2003; Liezmann, Klapp et al. 2011). 
The role of the immune system in asthma not only 
paves the way to enhancing disease management 
through conditioned placebo effects (Pacheco-
Lupez, Engler, Niemi, & Schedlowski, 2006), but 
also highlights the need to manage stress as a 
complement to pharmacological treatment.
In addition to the global immune pathways, 
the nervous system also appears to play a ma-
jor role in asthma, regulating local immune re-
sponse (Thayer & Sternberg, 2009).  As part of 
the parasympathetic nervous system (PSNS), the 
vagus nerve monitors visceral organs and modu-
lates immunological response through processes 
such as the cholinergic anti-inflammatory path-
way (Tracey, 2002).  Moreover, the sympathetic 
nervous system (SNS) modifies airway function 
through adrenergic activity due to fight-or-flight 
responses.  Rather than exerting opposing effects, 
however, the SNS and PSNS may work syner-
gistically to reverse inflammation.  Addressing 
the impact of central nervous system (CNS) in 
immune responses, researchers have observed 
neural correlates of asthmatic symptoms.  fMRI 
data demonstrates a significant correlation be-
tween the anterior cingulate cortex (ACC) and 
insula — areas involved in visceral perception, 
homeostasis and emotional regulation — and 
markers of inflammation and airway obstruction 
in asthma (Rosenkranz, Busse et al. 2005).  PET 
data corroborates the fMRI findings (Ohira et 
al., 2006).  These results reveal potential physi-
ological pathways for psychological influences on 
asthma symptoms.
Currently, numerous studies demonstrate 
the role of verbal suggestion on bronchial tone 
(Meissner, 2011).  Empirical inquiry into the ef-
fects of expectation in asthma dates back to the 
19th century, when a fake rose induced cold-
like symptoms, including pulmonary distress 
(Mackenzie, 1886).  Later studies showed that ad-
ministering saline while suggesting that it was a 
bronchoconstrictor could elicit bronchoconstric-
tion.  Conversely, pairing saline with the sugges-
tion that it was actually a bronchodilator reversed 
the initial bronchoconstricting effects (Butler 
& Steptoe, 1986; Luparello, Lyons, Bleecker, & 
McFadden, 1968; McFadden, Luparello, Lyons, & 
Bleecker, 1969).  In one recent study by Kemeny 
et al. (2007), FEV1 measurements indicated that 
placebo bronchodilators suppressed airway re-
sponse to subsequent methacholine administra-
tion.  Moreover, placebo effects in asthma may 
be organ specific.  One particular study reversed 
nocebo bronchoconstriction with a placebo 
bronchodilator, without alleviating the nocebo 
side-effects of increased heart rate and skin con-
ductance (Butler & Steptoe 1986).  These data de-
note the existence of truly objective physiological 
responses to suggestion.
Eosinophil 
A type of white blood cell 
associated with asthma and 
allergy.
HPA Axis 
The interaction between the 
Hypothalamic, Pituitary and 
Adrenal glands involved in 
mediating stress response.
Methacholine 
Synthetic molecule used 
in certain tests of airway 
hyperreactivity the results 
of which may be used to 
diagnose asthma.
Nocebo 
A term describing a placebo 
that has a detrimental effect 
on the patient
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While certain studies indicate that suggestion 
can indeed influence physiology, other studies 
found no significant contribution by suggestion 
to objective measures of lung function (Isenberg, 
Lehrer, & Hochron, 1992b), similar to the findings 
of Wechsler et al. in their recent paradigm.  Due 
to highly variable methodologies, none of these 
studies, refuting or supporting the reality of pla-
cebo effects in asthma, is conclusive or broadly 
generalizable.  In the fields of immunology and 
respirology, even clinical intuition is divided. 
Certain clinicians predict that placebos and sub-
sequent expectations merely alter perception, 
while others acknowledge the potential for objec-
tive changes (R. Anbar, F. Noya, personal com-
munication August 2011).  These discordant re-
ports nonetheless invite further investigation into 
the possibility of placebo effects in asthma, rather 
than grounds to dismiss it as Dr. Gorski does, on 
the basis of a single pilot study.
The Importance of  
Subjectivity
Despite the inconsistency of the asthma literature, 
many physicians dismiss subjective and psycho-
logical factors entirely, as Dr. Gorski does, in sin-
gular favour of pharmacological agents:
Asthma can and does kill, some 250 000 
deaths per year worldwide.  Choosing al-
ternative medicine over effective asthma 
treatment because placebo responses lead 
to feeling better without altering the un-
derlying illness, could very well lead to 
preventable asthma deaths.
While recognizing that asthma accounts for 
a sizable portion of disease burden on society 
(Morgan & Khan, 2003), psychosocial factors 
contribute greatly to its morbidity and mortal-
ity (Leigh, MacQueen, Tougas, Hargreave, & 
Bienenstock, 2003; Sodergren & Hyland, 1999; 
Strunk, Mrazek, Fuhrmann, & LaBrecque, 1985). 
For example, in a study where structured inter-
views compared children who died of asthma 
attacks with those who survived, identifiable fac-
tors such as family turmoil and emotional dis-
tress were significantly greater in those who sub-
sequently died (Miller & Strunk, 1989; Mrazek, 
Klinnert, Mrazek, & Macey, 1991).  Importantly, 
each patient presents with a unique profile of trig-
gers –from intrinsic (i.e., emotional) in addition 
to extrinsic (i.e., pollen, animal dander, etc.) fac-
tors (Isenberg, Lehrer, & Hochron, 1992a), and 
accordingly requires differential treatment.  For 
example, extant research demonstrates that par-
ents can exert a considerable impact on childhood 
asthma (Madrid & Monte Rio, 2005; Mrazek, 
Klinnert, Mrazek, & Macey, 1991; Weinstein, 
Chenkin, & Faust, 1997) specifically in cases with 
a strong emotional component to symptom onset. 
In some studies, children experienced symptom 
relief when they remained at home with a sur-
rogate (Purcell et al., 1969), whereas others dem-
onstrated exacerbation in response to separation 
(Miller & Wood, 2003).  Psychological factors 
play an apparent role in asthma symptomatology 
and deserve clinical attention accordingly.
Dr. Gorski disputes the clinical validity of 
quality-of-life metrics, and minimizes the im-
pact of subjective factors by equating asthma to 
an epidural hematoma, where feeling symptom-
free erroneously masks a potentially lethal condi-
tion.  This analogy falls short, however, because 
the symptoms for mild-to-moderate asthma such 
as coughing and wheezing do not correlate with 
underlying hypoxia — a condition that arises 
only in cases of extreme severity.  Dr. Francisco 
Noya, a pediatric immunologist at the Montreal 
Children’s Hospital, highlights that at this stage 
of asthma, “obstruction of airways does not affect 
oxygenation” but rather impairs regular breath-
ing loops (personal communication, August 
2011).  Concerns other than hypoxia, however, 
arise from this disruption.  Dr. Ran Anbar, a pe-
diatric pulmonologist at SUNY Upstate Medical 
University, clarifies that “these asthma symptoms 
can be disruptive to life: they can cause nighttime 
awakening, which prevents good quality sleep, 
which can lead to many problems such as poor 
school or job performance, or even obesity” (per-
sonal communication, August 2011).  Thus, while 
hypoxia is the most dire and life-threatening con-
sequence, it may not be the most pressing con-
cern in the cases of mild-to-moderate asthma. 
Though symptoms can serve as a warning 
sign in severe asthma exacerbations, an often un-
der-appreciated component requires direct men-
tion.  In certain instances, symptoms of coughing 
and wheezing may dissociate from objectively re-
duced lung function, even when these symptoms 
lead to hospitalization.  Where hospitalization 
appears as a routine component of asthma man-
agement, Dr. Ran Anbar asserts that: “Asthma can 
be managed — any time a patient with asthma has 
been hospitalized has either been mismanaged or 
didn’t take their medicine.” Dr Anbar specializes 
in the most intractable forms of pediatric asthma, 
and must often couple psychological interven-
tions with pharmacology to effectively manage 
his patients.  Recently published, self-hypnosis 
successfully managed a boy’s crippling external 
symptoms — previously unresponsive to medica-
tion — where lung function remained below aver-
age (Anbar & Sachdeva, 2011).  Here, Dr. Anbar 
rectified low lung function with appropriate 
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bronchodilators, while implementing psychologi-
cal management to supplement pharmacology’s 
deficits.  Evidently, psychology and subjectivity 
as adjuncts to pharmacology are key to disease 
management, the symptoms of which exert a pro-
found and immediate handicap on quality of life. 
Asthma provides a clinical forum for psychol-
ogy to work in concert with pharmacology to af-
fect stronger treatment outcomes.  Its prevalence 
continues to rise in the face of modern pharma-
cological treatments (Morgan & Khan, 2003) 
that, alone, are clearly inadequate to curb the rise 
in disease.  Harnessing psychological — or top-
down — processes may serve to boost therapeutic 
efficacy and also reduce dependence on medica-
tion.  As one case study illustrates, self-hypnosis 
allowed a patient with severe asthma to reduce 
systemic steroid intake (Anbar, 2003).  Larger 
studies would no doubt be necessary to investi-
gate the exact conditions under which these types 
of treatment are optimal, but such reports raise 
the potential for top-down processes to comple-
ment current pharmacology and bolster long-
term treatment outcomes.  
Dr. Gorski takes exception to Wechsler et al.’s 
discussion, as an assault by “quackademics” on 
Western medicine, interpreting that their claims 
of subjective improvement are “being sold to 
the public as evidence of “powerful” placebo ef-
fects and as evidence that we physicians should 
be doing more placebo medicine.” Dr. Moerman 
fuelled this outlook by over-generalizing the sub-
jective component of disease.  Granted, in specific 
instances, perception contributes significantly to 
the effectiveness of pharmacological treatment. 
For example, diazepam administered unbe-
knownst to anxious patients produced no clini-
cally meaningful decrease in symptoms (Colloca, 
Lopiano, Lanotte, & Benedetti, 2004), and covert-
ly withdrawing the medication did not precipitate 
rebound anxiety.  More broadly, a pessimistic 
view on personal health contributes to height-
ened incidences of disease and mortality (Idler 
& Benyamini, 1997; Mossey & Shapiro, 1982). 
Suggestion does play a role in human health, but 
the specific contexts in which these effects are 
most salient remains a subject for further inquiry.
Crucially, we must acknowledge that those 
who claim the omnipotence of subjectivity are 
just as misguided as those who discount its power. 
There are limits to what psychological factors can 
achieve and in certain instances responses can be 
illusory.  As an example, the idea that hypnotic 
suggestion can improve visual acuity is a pseu-
do-scientific myth.  The suggestion itself cannot 
change the optics of the eye, but only influences 
how effective the patient believes his eyesight to 
be (Raz, Marinoff, Zephrani, Schweizer, & Posner, 
2004).  Interpreting the import of subjective fac-
tors in disease requires moderation.  Rather than 
eschewing western medical techniques, we em-
phasize harnessing the mind, as adjunctive ther-
apy to complement current medical treatments.  
Future Directions
Certain scholars deem the whole placebo evi-
dence-base methodologically unsound –largely 
attributing the “placebo effect” to research ar-
tifact.  With two controversial meta-analyses, 
Hrobjartsson and Gotzsche (2001, 2004) evaluat-
ed RCTs for treatments of ailments such as pain, 
nausea and hypertension for valid placebo effects, 
and found that they only institute a small subjec-
tive benefit; however, several methodological is-
sues arise when relying on RCTs to observe place-
bo effects.  Some trials specifically screen subjects 
to include only those who are least likely to re-
spond to an inert substance (Busse & Lemanske, 
2009).  Moreover, because the processes of in-
formed consent diminish patient expectation for 
“active treatment”, the RCT design should display 
the weakest placebo effects in medicine (Foddy, 
2009).  Such methodological considerations em-
phasize the need for prospective study designs to 
examine placebo effects directly rather than rely-
ing on a-posteriori observations.
Understanding which characteristics com-
prise a good placebo reactor constitutes a solid 
aim of future study designs.  Front-runners of 
placebo research, however, acknowledge that re-
sponses to placebo are highly unreliable (Whalley, 
Hyland, & Kirsch, 2008) and that the search for 
predictive markers of susceptibility to placebo 
remains largely unsuccessful (Kaptchuk et al., 
2008).  One important factor that the literature 
in general, including the paper by Wechsler et al., 
neglects to explore is the role of age in placebo 
effects, as youth is emerging as a potential fac-
tor associated with susceptibility to suggestion. 
For example, children who suffer from migraine 
headaches also experience greater placebo effects 
than  adults (Fernandes, Ferreira, & Sampaio, 
2008; Lewis, Winner, & Wasiewski, 2005).  A re-
cent meta-analysis of anti-epileptic medications 
objectively verifies the elevated placebo effects in 
pediatric subjects; children in the placebo group 
were twice as likely as adults to achieve a 50% re-
duction in convulsive activity (Rheims, Cucherat, 
Arzimanoglou, & Ryvlin, 2008).  The literature 
suggests, but does not conclude, that children 
may demonstrate heightened placebo effects in 
general, and thus be more amenable to psycho-
logical interventions.
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Currently, our lab is designing and imple-
menting a study to directly address the role of 
placebo effects in pediatric asthma.  We comple-
ment the design of Wechsler et al. by controlling 
for factors such as age and verbal suggestion. 
Specifically in asthma, heightened placebo ef-
fects may accompany younger age (Kemeny et al., 
2007).  Our data should effectively contextualize 
the findings from Wechsler et al., and shed light 
on the relevance and role of suggestion in asthma 
management.  
Conclusion
Recent critiques of Wechsler et al. disparage at-
tempts to address placebo as the omnipresent 
silent partner in the care of asthma patients. 
Although pharmacological treatments are the 
proven cornerstone of management, psychoso-
cial factors may influence symptoms and improve 
disease outcomes.  Rather than endorsing place-
bos as panaceas, we advocate the need to further 
explore its potential as an adjunct to traditional 
therapies.  Embracing placebos, albeit judicious-
ly, as a viable tool of the clinical armamentarium 
paves the road to a more scientific understanding 
of mind–body regulation.
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